Scenario | Cost, $ | Screening as proportion of total cost | ||||
---|---|---|---|---|---|---|
Screening | Clinical investigation | Procedure* | Treatment† | Total | ||
No screening | 0 | 83 936 | 1 220 608 | 1 713 473 | 3 018 018 | 0.00 |
Annual age 40-49 yr, biennial age 50-69 yr | 4 551 101 | 49 334 | 1 479 841 | 1 788 107 | 7 868 384 | 0.58 |
Annual age 40-49 yr, biennial age 50-74 yr | 5 027 968 | 39 529 | 1 567 832 | 1 832 766 | 8 468 095 | 0.59 |
Annual age 40-69 yr | 6 540 531 | 40 605 | 1 530 563 | 1 694 982 | 9 806 681 | 0.67 |
Annual age 40-74 yr | 7 314 735 | 30 529 | 1 618 139 | 1 707 003 | 10 670 406 | 0.69 |
Annual age 50-69 yr | 4 127 472 | 47 245 | 1 487 568 | 1 713 469 | 7 375 754 | 0.56 |
Annual age 50-74 yr | 4 908 452 | 37 013 | 1 575 399 | 1 724 528 | 8 245 393 | 0.60 |
Biennial age 40-74 yr | 3 931 877 | 41 542 | 1 557 638 | 1 855 982 | 7 387 038 | 0.53 |
Biennial age 50-69 yr | 2 175 956 | 55 863 | 1 437 689 | 1 807 948 | 5 477 456 | 0.40 |
Biennial age 50-74 yr | 2 672 157 | 46 018 | 1 524 021 | 1 849 832 | 6 092 028 | 0.44 |
Triennial age 50-69 yr | 1 573 325 | 61 405 | 1 406 127 | 1 821 409 | 4 862 266 | 0.32 |
Triennial age 50-74 yr | 1 911 210 | 53 721 | 1 477 251 | 1 864 335 | 5 306 517 | 0.36 |
*Includes surgery and radiation costs.
†Includes systemic treatment with medications including trastuzumab.